What type of glomerulonephritis is PLAIR (Phospholipase A2 Receptor) associated with?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PLAIR is Associated with Membranous Nephropathy

Phospholipase A2 Receptor (PLA2R) is definitively associated with membranous nephropathy (MN), making option B the correct answer. 1

Understanding PLA2R and Membranous Nephropathy

PLA2R is a key biomarker in membranous nephropathy, serving as both a diagnostic indicator and a target for monitoring disease activity. The relationship between PLA2R and membranous nephropathy has been well-established in recent clinical guidelines:

  • PLA2R antibodies are highly specific for primary membranous nephropathy
  • According to KDIGO 2021 guidelines, a positive anti-PLA2R antibody test in a patient with nephrotic syndrome is sufficient to diagnose membranous nephropathy even without kidney biopsy 1
  • PLA2R antibody levels can be used to monitor treatment response and guide therapy adjustments 1

Diagnostic Significance

The diagnostic value of PLA2R testing is so significant that recent guidelines have changed the diagnostic approach to membranous nephropathy:

  • A kidney biopsy is no longer required to confirm MN in patients with nephrotic syndrome and positive anti-PLA2R antibodies 1
  • PLA2R staining in kidney biopsy samples can identify membranous nephropathy even in patients who are seronegative for circulating antibodies 1
  • Approximately 52% of patients with primary membranous nephropathy test positive for PLA2R antibodies 2

Clinical Implications

The identification of PLA2R has revolutionized the management of membranous nephropathy:

  • PLA2R antibody levels can be monitored every 3-6 months during treatment 1
  • Disappearance of anti-PLA2R antibodies typically precedes clinical remission 1
  • Rising antibody levels may predict disease relapse and guide preemptive therapy 3

Important Caveats

While PLA2R is strongly associated with primary membranous nephropathy, there are important considerations:

  • PLA2R positivity does not completely rule out secondary causes of membranous nephropathy
  • Secondary causes should still be evaluated, including malignancy, infections, and autoimmune diseases 1
  • Some cases of secondary membranous nephropathy, including those associated with sarcoidosis 4 and possibly lymphoma 5, can also show PLA2R positivity
  • A subset of PLA2R-associated MN patients may have circulating antibodies but negative staining on kidney biopsy, which may represent a more severe disease phenotype 6

Differential Diagnosis

It's important to distinguish membranous nephropathy from other glomerular diseases:

  • Minimal change disease (option A) is not associated with PLA2R antibodies
  • Goodpasture's syndrome (option C) is associated with anti-GBM antibodies, not PLA2R 1
  • While some cases of anti-GBM disease can be associated with monoclonal gammopathy, this is distinct from the PLA2R-associated membranous nephropathy 1

The evidence clearly demonstrates that PLA2R is specifically associated with membranous nephropathy, making option B the correct answer.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011

Guideline

Treatment of Primary Membranous Nephropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015

Research

Clinicopathological Characteristics and Outcomes of PLA2R-Associated Membranous Nephropathy in Seropositive Patients Without PLA2R Staining on Kidney Biopsy.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.